<DOC>
	<DOCNO>NCT00328770</DOCNO>
	<brief_summary>This study investigate whether sirolimus could decrease rate hepatoma recurrence liver transplantation high risk hepatoma patient .</brief_summary>
	<brief_title>De Novo Sirolimus-based Immunosuppression After Liver Transplantation Hepatocellular Carcinoma</brief_title>
	<detailed_description>A total 70 patient HCC ( mean age : 54.6 year , female/male : 12/58 ) receive liver transplant include study . Immunosuppression include de novo sirolimus , low-dose calcineurin inhibitor 6 12 month , short-course ( 3 month ) steroid .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Adult patient hepatocellular ( HCC ) carcinoma receive liver transplant Exclusion criterion : Patients le 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>liver transplant</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>sirolimus</keyword>
</DOC>